Neelapu SS, Locke FL, Bartlett NL, et al. Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). ASH 59th Annual Meeting & Exhibition, abstract 578.
T-cellymfoom na CAR T-celtherapie zeldzaam; genetische modificatie van cellen niet altijd de oorzaak
nov 2024 | Lymfoom